🩸Facts about Multiple Myeloma:

Treatment Sequencing and Combinations

#MultipleMyeloma #Hematology #MedEd #HEMEHUB #Daratumumab #BispecificAntibodies #Teclistamab #IMiDs #Lenalidomide #Pomalidomide #Carfilzomib #Immunotherapy #Oncology

La #FDA accepte la demande d'autorisation de mise sur le marché de l' #Ibérdomide 💊 pour le #MyélomeMultiple 🩸

Les résultats de l’essai de phase 3 #EXCALIBER ont montré une meilleure réponse, des taux de négativité #MRD plus élevés, par rapport au #Daratumumab 💊

www.targetedonc.com/view/fda-acc...

🩸📊Today’s question highlights long-term outcomes from the MajesTEC-3 trial.

See the answer and explanation on the next slide!

#MultipleMyeloma #MedEd #Hematology #Teclistamab #Daratumumab #BispecificAntibodies #ClinicalTrials #HemeOnc #MedEd #MajesTEC3 #HEMEHUB

🩸 Today’s question focuses on combination therapy evaluated in the MajesTEC-3 trial for relapsed/refractory multiple myeloma (RRMM).

See the answer and explanation on the next slide!

#MultipleMyeloma #Teclistamab #Pomalidomide #Daratumumab #Elranatamab #Carfilzomib #Talquetamab #Hematology

🩸Facts about Multiple Myeloma:

Clinical Efficacy and Survival Outcomes

#MultipleMyeloma #BispecificAntibodies #Immunotherapy #Teclistamab #Elranatamab #Daratumumab #ClinicalTrials #Oncology #HematologicMalignancies #CancerTherapy #HEMEHUB

🩸🔬Today's question!

See the answer and explanation on the next slide.

#MultipleMyeloma #MAIATrial #FrontlineTherapy #Hematology #HemeOnc #ClinicalTrials #CancerTherapy #HEMEHUB #CyBorD #Daratumumab #Lenalidomide #Dexamethasone #DRd #Bortezomib #Thalidomide #Pomalidomide

FDA Approves Daratumumab (Darzalex Faspro) Plus VRd for Transplant-Ineligible Newly Diagnosed Multiple Myeloma - OncoDaily FDA Approves daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed, transplant-ineligible multiple myelom...

FDA Approves Daratumumab (Darzalex Faspro) Plus VRd for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Daratumumab #MM #MultipleMyeloma

📢 #FDA approves #daratumumab and hyaluronidase-fihj plus #VRd for adults with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.

Learn more about frontline advances in our upcoming session with Paul Richardson, MD, and Adeel Khan, MD.

#Hematology #MultipleMyeloma

Pharmacy in Heart and Lung Transplant: The Latest Studies in ISHLT Journal Watch The first Journal Watch of 2026 explores topics in transplant pharmacy, including valganciclovir for CMV, daratumumab monotherapy, and renal sparing in heart transplant recipients.

The January #ISHLTJournalWatch focuses on topics in #transplant #pharmacy, edited by Colleen Hutchinson. 💊

Topics include the NUDT16 genotype, #daratumumab monotherapy, & early mammalian target of rapamycin inhibitor (#mTORi).

🔗 www.ishlt.org/about/news-d...

#TransplantSky #PharmSky

Millions Missing Stavanger FB-Screenshot der Übersetzung aus dem Norwegischen. 4 + 4 MILLIONEN FÜR HAUKELAND Der ME-Fonds gab kürzlich bekannt, dass er neue 4 Millionen Kronen in die Studie am Daratumumab am Haukeland überwiesen hat! Ende Mai 2025 betrug der Status des ME-Fonds 2,4 Millionen. Ende des Jahres lag der Status bei 4,4 Millionen Kronen. Satte 2 Millionen NOK sind nach Bekanntgabe der Studie Anfang Juni 2025 also gesammelt worden. VIELEN DANK an alle, die dazu beigetragen haben!! Der ME-Fonds hat bei Ankündigung der Studie im vergangenen Jahr auch 4 Millionen überwiesen und hat nun mit insgesamt 8 Millionen Kronen beigetragen! Die Studie hat, wie Sie wissen, keine öffentliche Unterstützung erhalten, und es bleiben etwa 3,5 Millionen (norwegische Kronen), bis die Studie vollständig finanziert ist.

Millions Missing Stavanger FB-Screenshot der Übersetzung aus dem Norwegischen. QUELLEN Juni 2025: "ME-Fonds stellt vier Millionen für eine groß angelegte klinische Studie am Daratumumab im Haukeland zur Verfügung" https://www.me-foreningen.no/me-fondet-gir-fire -millioner-til-daratumumab-studie-pa-haukeland/ 19. Januar 2026: "ME-Fonds stellt ResetME 4 neue Millionen zur Verfügung" https://www.me-foreningen.no/me-fondet-gir-4-nye -millioner-til-resetme/

News aus Norwegen im Screenshot.
#MEcfs
#Daratumumab

Millions Missing Stavanger (FB)

Quellen:
www.me-foreningen.no/me-fondet-gi...

www.me-foreningen.no/me-fondet-gi...

Blog: Unterstütze die ME-Studie:
lifewithmebysissel.wordpress.com/2025/06/22/s...

ME-Verein:
www.spleis.no/project/451742

Among older and frail patients with #MultipleMyeloma #MMsm, a dexamethasone-sparing regimen with #daratumumab and #lenalidomide reduced the risk of progression or death compared with lenalidomide and #dexamethasone alone, at a PFS of 53.4 vs. 22.5 months: https://ow.ly/YXzG50XT7Aw
#HemeSky #OncSky

Résultats #Majestec_3, le Dr Mateos a présenté le #LBA_6 : Étude randomisée de phase 3 du #Teclistamab plus #Daratumumab versus choix de l’investigateur entre dara et #Dexaméthasone avec #Pomalidomide ou #Bortézomib (#DPd/#DVd) chez des patients atteints de #MyélomeMultiple R/R

bsky.app/profile/did:...

#DARATUMUMAB
multi-search-tag-explorer.allgraph.ro/advanced-sea...
#GEORGE #HENDERSON #ARCHITECT
multi-search-tag-explorer.aepiot.com/advanced-sea...
#THE #AMERICAN #CANCER #SOCIETY
allgraph.ro/advanced-sea...
headlines-world.com

Resolving the Interference of Anti‐CD38 Antibodies on Blood Compatibility Assays Using CD38 “Baitbodies” Approach Blood transfusion safety depends on swift blood compatibility testing. Alloantibodies recognizing these blood group antigens determine blood compatibility, and the transfusion of incompatible blood c...

A CD38 "baitbody" to support safe blood products for multiple myeloma patients receiving Daratumumab and Isatuximab.
onlinelibrary.wiley.com/doi/full/10....

#baitbody, #daratumumab, #felzartamab, #isatuximab, #transfusionmedicine, #antibody, #fusionprotein, #bloodcompatability, #CD38, #MM

MajesTEC-3 supports teclistamab–daratumumab for relapsed/refractory multiple myeloma Phase 3 trial data show a significant improvement in progression-free survival with use of teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma.

From #ASH2025 - Phase 3 trial data show a significant improvement in progression-free survival with use of #teclistamab plus #daratumumab for patients with relapsed or refractory #MultipleMyeloma.

👉 buff.ly/7bKRL6f

#OncSky

Antibody-based combination therapy with #teclistamab and #daratumumab was shown to be highly effective in elderly patients with newly diagnosed #MultipleMyeloma #MMsm, producing a VGPR or better in 79% of patients and MRD negativity in 100% at six months: https://ow.ly/KQKn50XMHAW
#HemeSky #MedSky

Un nouvel espoir pour les patients atteints de myélome multiple - ON HEALTH Johnson & Johnson vient d'annoncer des résultats prometteurs pour une nouvelle immunothérapie contre le myélome multiple.

J&J vient de présenter des résultats prometteurs dans le #MyélomeMultiple 🩸

L’étude de phase 2 #MajesTEC_5 a évalué une association de 2 💊, le #Teclistamab & #Daratumumab & #Hyaluronidase, en 1ère ligne chez des patients éligibles à une #GreffeDeMoelle

on-health.tv/un-nouvel-es...

#Daratumumab is safe and effective in allowing patients with #iTTP to achieve ADAMTS13 remission. Presented at #ASH25.

https://bit.ly/48HbIb9

Significant Progress in Treating Relapsed Refractory Multiple Myeloma with Tec-Dara Combination Therapy A recent trial has revealed that the Tec-Dara combination therapy significantly outperforms standard treatments in relapsed refractory multiple myeloma, offering new hope to patients.

Significant Progress in Treating Relapsed Refractory Multiple Myeloma with Tec-Dara Combination Therapy #USA #Orlando #Multiple_Myeloma #Daratumumab #Teclistamab

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis Background and Significance: Systemic immunoglobulin light chain (AL) amyloidosis remains a challenging disease, with current frontline regimens faili…

#teclistamab and #daratumumab as the first treatment for people with a new diagnosis of AL-amyloidosis. Details via #ASH25 (2/2) clinicaltrials.gov/study/NCT071...

Sign the Petition Call for Funding a New Clinical Study on Daratumumab for ME/CFS

Petitie voor financiële steun voor een Noorse studie naar #daratumumab tegen #ME.

Tekenen en Repost = 💙

FDA Approval of Daratumumab Opens Treatment Options for High-Risk Smoldering Myeloma | OncLive Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

FDA approves daratumumab, giving patients with high-risk smoldering myeloma a powerful new treatment option and fresh hope.
#TCSC #Myeloma #CancerResearch #Daratumumab #FDAApproval #Hematology #Oncology #MedicalNews #CancerTreatment #HealthInnovation www.onclive.com/view/fda-app...

Combination treatment with #talquet­amab plus #daratumumab demonstrated deep, durable responses in patients with heavily pretreated R/R #MMsm #myeloma, with 71% and 82% achieving a response, and safety consistent with each as monotherapy: https://ow.ly/cSkt50Xv8vP
#HemeSky #MyelomaSky #OncSky

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Daratumumab #MM #Myeloma

FDA Approves Subcutaneous Daratumumab for High-Risk Smoldering Multiple Myeloma | OncLive The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

🚨 BREAKING 🚨

Le #Daratumumab 💉 sous-cutané est maintenant approuvé par la #FDA pour le #MyélomeMultiple 🩸 latent à haut risque, sur la base des résultats positifs de l’essai #AQUILA

Pour tout savoir à ce sujet : 📰
www.onclive.com/view/fda-app...

Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome Published in Expert Opinion on Biological Therapy (Vol. 25, No. 5, 2025)

Gute Übersicht zum aktuellen Forschungsstand (04/2025) von Autoantikörper-gerichteten Therapien bei #LongCovid & #MECFS

Vergleich aktueller Erkenntnisse zu #Rituximab, #Efgartigimod, #Daratumumab, #Immunadsorption, #BC007 & #IVIG

Die Tabelle im Link bietet eine schnelle Übersicht der Ergebnisse.

Is het juiste B-celafbrekende medicijn voor ME/cvs gevonden? Daratumumab blinkt uit in pilootstudie - ME-Gids.net De kernpunten We zijn terug bij de B-cellen, en dat brengt ons weer naar het 3de Internationale ME/cvs- en long covid-congres van Charité. B- en T-cellen zijn de twee belangrijkste spelers in de adapt...

Wat een hoopvol bericht!

In een kleine pilotstudie met 10 ME-patiënten verbeterden 6 van die 10 aanzienlijk na behandeling met #daratumumab. Een aanvraag voor een dubbelblind placebostudie met 66 patiënten is gedaan 🙏🙏

#ME #MECFS #MECVS #LongCovid

New Data on Daratumumab-Based Therapy for Untreated Multiple Myeloma in Japan Recent findings reveal that the daratumumab-based four-drug therapy significantly improves treatment outcomes for untreated multiple myeloma patients in Japan, aligning with global data.

New Data on Daratumumab-Based Therapy for Untreated Multiple Myeloma in Japan #Japan #Tokyo #Multiple_Myeloma #Daratumumab

Frontiers | Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent...

treat bone marrow cancer and a blood disease, among other things.

Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study (Updated)

www.frontiersin.org/journals/med...

#ME/CFS #pwME #Daratumumab

The last slide from the August 2025 issue of Journal Watch, titled "Daratumumab monotherapy as a desensitization strategy prior to cardiac transplantation." For a more screenreader friendly version, the full issue PDF is at https://www.ishlt.org/docs/default-source/journal-watch/2025-08-journalwatch-cardiology.pdf.

The final study of last month's #ISHLTJournalWatch in #cardiology is from @jhlt.bsky.social.

#HasanSiddiqi reviews a study exploring #Daratumumab monotherapy as a #desensitization strategy prior to #HeartTx.

#cardiosky #transplantsky